Fungal Diagnostics Research Update | 12–19 October 2026
This week’s fungal diagnostics research examines three important challenges for clinical microbiology laboratories: interpreting fungal growth in respiratory specimens, detecting antifungal resistance, and using molecular typing to understand differences between fungal strains.
The studies illustrate an increasingly important distinction in medical mycology: detecting and identifying a fungus is only the beginning. Laboratories must also help clinicians determine whether the organism is causing disease, whether treatment is likely to be effective, and what additional investigations may be required.
1. Does the amount of Candida in sputum help explain respiratory illness?
Candida species are frequently isolated from respiratory specimens, particularly in hospitalised patients. However, their presence usually reflects colonisation rather than invasive fungal pneumonia.
This creates a diagnostic challenge. A positive fungal culture may be clinically relevant, but it does not necessarily establish that Candida is responsible for a patient’s respiratory illness.
Researchers in China investigated whether measuring the quantity of Candida in sputum could provide additional information about the respiratory microbiome and airway inflammation.
The study included 140 hospitalised patients with suspected pulmonary infection. Researchers combined quantitative fungal culture with metagenomic next-generation sequencing (mNGS), allowing them to examine both fungal burden and the wider microbial community.
Patients were grouped according to their clinical and microbiological findings, including whether Candida was repeatedly isolated.
What did the researchers find?
Higher Candida loads were associated with changes in the composition of the respiratory microbiome.
Patients with greater fungal burdens showed:
- Reduced microbial diversity.
- Greater disruption of the normal respiratory microbial community.
- Lower relative abundance of several bacterial genera commonly found in the respiratory tract.
- Associations between microbiome composition and clinical factors, including hospital stay and invasive medical devices.
These findings suggest that the quantity of Candida present in sputum may provide information beyond a simple positive or negative culture result.
Why does this matter for diagnostic laboratories?
Quantitative fungal culture could potentially contribute to the interpretation of complex respiratory samples, particularly when combined with molecular microbiology and clinical information.
However, an important distinction remains.
A high Candida count in sputum does not prove invasive pulmonary candidiasis.
The study did not establish invasive infection through histopathological confirmation. The observed relationships between fungal burden and microbiome disruption also cannot establish whether Candida caused those changes or proliferated because the respiratory environment was already disturbed.
The findings are therefore best regarded as evidence that fungal burden may be a useful research marker of respiratory microbial disturbance, rather than validation of a diagnostic threshold for Candida pneumonia.
Laboratory implication: Reporting the presence of Candida remains different from diagnosing invasive fungal disease. Quantitative results may eventually provide additional context, but they require clinical validation before being used to guide treatment decisions.
Research: Wang G et al. Association of quantitative sputum Candida load with respiratory dysbiosis and airway inflammation in suspected invasive pulmonary candidiasis. mSystems, 2026.
2. Antifungal resistance surveillance: lessons from a laboratory in Zambia
Antifungal susceptibility testing is essential when infections are caused by organisms with unpredictable or reduced susceptibility to commonly used medicines.
However, access to fungal identification and susceptibility testing remains uneven internationally. This makes it difficult to establish reliable local resistance patterns and develop appropriate antifungal stewardship programmes.
Researchers in Zambia examined laboratory records of 57 Candida isolates collected between October 2024 and October 2025.
Most isolates came from vaginal swabs, with smaller numbers recovered from urine and respiratory specimens.
What did the researchers find?
Candida albicans accounted for 43 of the 57 isolates (75.4%).
Among these isolates, the researchers reported:
- Fluconazole resistance in approximately 7.5%.
- Differences in susceptibility between Candida species.
- Resistance to several antifungal agents among some non-albicans Candida isolates.
The authors also highlighted challenges in interpreting susceptibility results for organisms such as Candida glabrata, where drug-specific breakpoints and testing variability require particular care.
Why does this matter for diagnostic laboratories?
The findings reinforce the importance of identifying Candida to species level rather than assuming that all isolates have similar susceptibility patterns.
They also demonstrate why laboratories need locally generated susceptibility data.
Resistance estimates from one geographical area or patient population cannot necessarily be applied elsewhere.
There are important limitations to this study. The sample was small, most isolates came from the female reproductive tract, and some species were represented by only a handful of isolates.
Consequently, the reported resistance percentages should not be interpreted as national prevalence estimates for Zambia.
Laboratory implication: Species identification, reliable susceptibility methods, appropriate interpretive criteria and ongoing surveillance are all important components of antifungal stewardship.
Research: Chileshe M et al. Antifungal resistance patterns of Candida species isolated from a private laboratory in Zambia: implications for antifungal stewardship programs. JAC-Antimicrobial Resistance, 2026.
3. Can genetic typing help identify fungal strains with reduced antifungal susceptibility?
Molecular typing is increasingly used to investigate fungal outbreaks, transmission patterns and the geographical distribution of pathogens.
An important question is whether genetic differences between strains can also help predict their susceptibility to antifungal medicines.
Researchers investigated this possibility in Sporothrix brasiliensis, a fungus responsible for an expanding outbreak of sporotrichosis in parts of South America.
The infection can spread from infected cats to humans, making it an important concern for both medical and veterinary microbiology.
The study examined 92 fungal isolates from Brazil, Argentina and Paraguay.
Researchers combined multilocus sequence typing (MLST) with laboratory susceptibility testing against itraconazole, terbinafine and amphotericin B.
What did the researchers find?
The isolates belonged to several genetic groups, or haplotypes.
One group, designated H2, was particularly notable:
- Five of seven H2 isolates (71.4%) were classified as non-wild-type.
- Six of the remaining 85 isolates (approximately 7.1%) were non-wild-type.
A non-wild-type result indicates a susceptibility pattern outside the expected distribution for the organism and may suggest acquired or emerging resistance mechanisms.
However, it does not necessarily establish clinical resistance or predict treatment failure.
The association between the H2 genetic group and non-wild-type susceptibility was statistically significant, although the number of isolates in this group was small.
Why does this matter for diagnostic laboratories?
The study demonstrates the potential value of combining molecular epidemiology with conventional antifungal susceptibility testing.
Genetic typing may help laboratories identify populations of fungi that warrant closer surveillance for reduced susceptibility.
It could also contribute to understanding how resistant strains spread between geographical regions and animal and human populations.
However, these findings do not establish that MLST can replace susceptibility testing or reliably predict individual treatment outcomes.
Laboratory implication: Molecular typing and phenotypic susceptibility testing provide complementary information. Their combination may strengthen surveillance, particularly for emerging fungal pathogens.
Research: de Souza Rabello VB et al. Susceptibility Profiles Among Sporothrix brasiliensis Genotypes in the Ongoing Zoonotic Sporotrichosis Epidemic in Brazil, Argentina and Paraguay. Mycopathologia, 2026.
Diagnostic technology to watch: MALDI-TOF beyond conventional culture
MALDI-TOF mass spectrometry has transformed routine microbial identification by allowing laboratories to identify many bacteria and fungi rapidly from cultured material.
A short perspective published this week asks whether the technology can be extended to organisms that are difficult or impossible to cultivate using conventional methods.
The question is particularly relevant to fungal diagnostics, where culture may be slow, insensitive or unsuccessful despite clinical evidence of infection.
Extending mass-spectrometry identification beyond conventional colonies could potentially improve diagnostic workflows. However, analytical sensitivity, specimen preparation, reference databases and clinical validation remain important challenges.
This publication is a perspective rather than a new clinical validation study, so it should be viewed as a discussion of future possibilities rather than evidence of an established diagnostic method.
Research: Mukhida S et al. Beyond the colony: can MALDI-TOF identify non-cultivable bacteria and fungi? Future Microbiology, 2026.
What can we learn from this week’s research?
These studies highlight three principles relevant to clinical fungal diagnostics.
Detection is not the same as diagnosis. Identifying fungal organisms in clinical specimens requires interpretation in the context of the patient’s condition, the sample type and the likelihood of colonisation or contamination.
Antifungal susceptibility is species- and strain-dependent. Accurate identification and reliable susceptibility testing remain essential, particularly as resistance patterns change.
Molecular methods are becoming increasingly valuable. Sequencing and genetic typing can improve our understanding of fungal populations and emerging resistance, but their clinical utility must be demonstrated rather than assumed.
Together, these developments reinforce the importance of integrating conventional mycology, molecular diagnostics, susceptibility testing and clinical expertise.
The future of fungal diagnostics is not simply about detecting more organisms. It is about producing laboratory results that are more accurate, interpretable and useful for patient care.
This weekly update summarises recently published research relevant to medical mycology laboratories, clinicians and researchers. Individual studies may have methodological limitations, and emerging diagnostic approaches require appropriate validation before routine clinical implementation.